Related Experiment Video

Updated: Apr 5, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.8K

Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases

Pei-Jie Chen1, Shuang-Peng Cai1, Cheng Huang1

  • 1School of Pharmacy, Laboratory of Bioactivity of Natural Products, Anhui Medical University, Hefei 230032, China; Institute for Liver Diseases of Anhui Medical University (ILD-AMU), Anhui Medical University, Hefei 230032, China.

Toxicology
|August 25, 2015
PubMed

Insights

Protein tyrosine phosphatase 1B (PTP1B) is crucial for physiological balance. This review explores PTP1B

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Hepatology

Background:

  • Tyrosine phosphorylation regulates vital physiological processes.
  • Protein tyrosine phosphatase 1B (PTP1B) is a key enzyme in this pathway.
  • Dysregulation of PTP1B is implicated in metabolic and liver diseases.

Purpose of the Study:

  • To review the multifaceted roles of PTP1B in various liver diseases.
  • To highlight PTP1B as a potential therapeutic target in hepatology.
  • To discuss PTP1B's involvement in liver regeneration, injury, and cancer.

Main Methods:

  • Literature review of PTP1B function in liver pathophysiology.
  • Analysis of PTP1B's role in cellular processes like hepatocyte survival and lipogenesis.
  • Examination of PTP1B's involvement in specific liver conditions.

Main Results:

  • PTP1B significantly impacts liver regeneration and drug-induced liver injury.
  • PTP1B plays a critical role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD).
  • PTP1B is implicated in the development and progression of hepatocellular carcinoma.

Conclusions:

  • PTP1B is a central regulator in liver homeostasis and disease.
  • Targeting PTP1B offers a promising therapeutic strategy for diverse liver ailments.
  • Further research into PTP1B modulation is warranted for liver disease treatment.
Keywords:
Drug-induced liver disease (DILI)Hepatocellular carcinoma (HCC)Liver regenerationNon-alcoholic fatty liver disease (NAFLD)Protein tyrosine phosphatase 1B (PTP1B)

More Related Videos

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

878
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
651
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.6K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.9K